‘DrugAbacus’ Pricing Tool Helps Payers Calculate Fair Value Of Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Memorial Sloan Kettering’s Peter Bach unveils a web-based drug pricing tool that uses several value measurements, including R&D investment and novelty, to identify the appropriate price for cancer drugs.
You may also be interested in...
As Drug Value Frameworks Gain Traction, Patients Seek More Input
'Patients are ready and willing to have conversations' about trade-offs, National Health Council's Perfetto says.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.